Q&A: A missing conversation on the price of cancer drugs
13 May 2016
A novel approach to judge which new cancer drugs are worth reimbursing is emerging within the European Organisation for Research and Treatment of Cancer, an independent research group. Denis Lacombe, its director general, says the growing understanding of tumor biology can equip European authorities to make more informed decisions based on performance in real-life conditions. In an interview with POLITICO, he suggested how to ease access to the evidence that could radically improve decision-making.
The read the full article on the Politico Pro website.
Related News
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
